bluevac
Bluevac is key in controlling the bluetongue virus (serotypes 1, 3, 4 and 8) in sheep and cattle. Its active immunization is crucial to combating the spread of the disease to new locations.
BLUEVAC BTV
Line of inactivated vaccines to prevent and control the disease caused by the bluetongue virus (serotypes 1, 4, and 8) in sheep and cattle.
BLUEVAC-3
Inactivated vaccine to prevent and control the disease caused by the bluetongue virus serotype 3 in sheep and cattle.
BLUEVAC MULTISTRAIN
Line of inactivated vaccines to prevent and control the disease caused by several bluetongue virus serotypes (1+4, 4+8, and 1+8) in sheep and cattle.
More than 230 million doses of Bluevac have been administered in Europe, which shows that Bluevac vaccination is a valuable tool for preventing the disease and one of the best options to reduce clinical signs and viremia in sheep and cattle herds.
Bluevac uses aluminum hydroxide and Quil-A as adjuvants. Quil-A is a purified derivate of saponin that blocks viral antigens and slows them down so they can be trapped by the vaccinated animal’s immune cells.
01
Bluevac doesn’t trigger serious local reactions.
02
No viral genome present after vaccination.
03
Widely tested and validated with RT-PCR testing.
04
Reduces symptoms in sheep livestock.
05
The cost of a dose is very low compared to the losses due to infections with clinical signs and decreased yield and fertility.
06
Decreases the spread to healthy animals, lowering the prevalence of the disease in endemic zones.
07
There are fewer restrictions on mobility of vaccinated animals between regions and countries.
08
The flexible plastic bottle doesn’t require ventilated extraction equipment.